OCTON HEALTH 360
Holistic clinical AI
 All cancers
Use with patients
Cancer module

Prostate Cancer

PSA-driven mpMRI surveillance with PI-RADS v2.1 categorization.

Reporting system
PI-RADS v2.1 (1–5)
Imaging modalities
  • Multiparametric MRI
  • Transrectal Ultrasound
  • PSA + free-PSA
  • MRI-fusion biopsy
  • Pathology
Key findings OCTON surfaces
  • PI-RADS 4–5 peripheral-zone lesion
  • Marked DWI restriction with low ADC
  • Early dynamic enhancement curve
  • Extracapsular extension / seminal-vesicle invasion
  • Suspicious tumor in transition zone
Evidence base
  • NCCN Prostate Cancer Early Detection v3.2025
  • AUA / SUO Localized Prostate Cancer 2024
  • EAU Guidelines on Prostate Cancer 2024
Risk questionnaire
  • · What is your age?
  • · First-degree relative with prostate / breast / ovarian cancer?
  • · Confirmed BRCA1 / BRCA2 / HOXB13 carrier?
  • · African / Caribbean ancestry?
  • · Most recent PSA ≥ 3.0 ng/mL?
  • · New-onset lower-urinary-tract symptoms / haematuria?
See OCTON in action · early-detection demos
07 / 24
Prostate cancerYou're herehigh · 76/100mpMRI · PI-RADS 4
PI-RADS 4 lesion in a BRCA2 carrier flagged on mpMRI surveillance
PI-RADS 4 lesion in the right peripheral zone (1 mL) — significant DWI restriction with focal early enhancement.
View demo
Ready to use this module?
Open OCTON and analyze a scan.
Start